Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2017, the company has rapidly established itself as a leader in developing innovative therapies for ocular diseases, particularly focusing on unmet medical needs in the eye care sector. Tarsus is renowned for its flagship product, TP-03, a groundbreaking treatment for Demodex blepharitis, which sets itself apart through its targeted mechanism of action and potential to transform patient care. With a commitment to advancing ocular health, Tarsus has achieved significant milestones, including successful clinical trials and strategic partnerships that bolster its market position. As it continues to expand its operational reach, Tarsus Pharmaceuticals remains dedicated to delivering unique solutions that enhance the quality of life for patients worldwide.
DitchCarbon Score
How does Tarsus Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tarsus Pharmaceuticals, Inc.'s score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Tarsus Pharmaceuticals, Inc.'s reported carbon emissions
Tarsus Pharmaceuticals, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As of now, Tarsus Pharmaceuticals has not inherited any emissions data from a parent or related organization, and there are no industry-standard climate initiatives such as SBTi or CDP targets reported. This lack of data suggests that the company may still be in the early stages of developing its climate commitments or reporting framework. In the context of the pharmaceutical industry, companies are increasingly expected to establish clear climate strategies and emissions reduction targets. Tarsus Pharmaceuticals may need to consider adopting such initiatives to align with industry standards and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Tarsus Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
